- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06224855
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
An Open-label Dose Escalation and Cohort Expansion Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and and Efficacy of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Prof. Zhang Li
- Phone Number: +86-020-87343565
- Email: zhangli@sysucc.org.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient voluntarily signed the informed consent form and followed the protocol requirements.
- Gender is not limited.
- Age ≥ 18 years old.
- Expected survival time ≥ 3 months.
- The Eastern Cooperative Oncology Group (ECOG) score 0-2.
- Subjects may provide biopsy or archival tumor tissue samples for the central laboratory to confirm expression levels of Target protein.
- Patients with solid tumors or hematologic tumors who have failed standard therapy, including small cell lung cancer, multiple myeloma, neuroblastoma, etc..
Patients who have received ASCT treatment must meet the following conditions:
- ASCT > 100 days from start of study treatment.
- no active infection.
- Toxicity from prior antineoplastic therapy has recovered to Grade ≤ 1 (except alopecia) as defined by NCI-CTCAE v5.0, including peripheral neuropathy ≤ Grade 2.
- Organ function must meet the following requirements: blood routine:
(1) Patients with multiple myeloma: absolute neutrophil count (ANC) ≥ 1.0×109/L (previous use of granulocyte colony-stimulating factor [G-CSF] is allowed, and G-CSF is not allowed within 7 days before laboratory examination during the screening period);Platelet count ≥ 50×109/L (platelet transfusion is not allowed within 7 days before laboratory tests during the screening period).
Hemoglobin (HGB) ≥ 75 g/L (prior red blood cell [RBC] transfusions or recombinant human erythropoietin are allowed; Within 7 days before the laboratory examination during the screening period, red blood cell transfusion is not allowed).
(2) Other patients: Absolute neutrophil count (ANC) ≥ 1.5×109/L, Platelet count ≥ 100×109/L, Hemoglobin (HGB) ≥ 90 g/L Liver: total bilirubin (TBIL) ≤ 1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert's syndrome (direct bilirubin ≤ 1.5×ULN); Glutamate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤ 3.0×ULN.
In the presence of liver metastases, both AST and ALT ≤ 5× ULN Kidney: creatinine clearance (Ccr) ≥ 30mL/min in patients with multiple myeloma, Creatinine ≤ 1.5×ULN in other patients.
Coagulation:
International Normalized Ratio (INR) ≤ 1.5, Activated partial thromboplastin time (APTT) or prothrombin time (PT) ≤ 1.5× ULN.
corrected serum calcium ≤ 14 mg/dL (≤ 3.5 mmol/L). left ventricular ejection fraction (LVEF) ≥ 50%. 11. The patient and his/her spouse agree to take effective contraceptive measures (excluding contraception during the safe period) from the time of signing the informed consent form to 6 months after the last dose.
Exclusion Criteria:
- Within 14 days before the first dose: received plasmapheresis; Treatment with > 10 mg of prednisone or equivalent doses of systemic corticosteroids per day for more than 3 consecutive days (short-term use for the prevention of contrast allergy can be enrolled).
- Patients have received systemic anti-myeloma therapy or investigational drug therapy within 28 days or 5 half-lives (whichever is shorter) prior to the first dose; Radiotherapy within 14 days prior to the first dose.
- Patients have received monoclonal antibody therapy within 30 days before the first dose.
- Patients have received autologous hematopoietic stem cell transplantation within 100 days before the first dose.
- Patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) or have a history of solid organ transplantation.
- Patients have received the same targeted therapy in the past (limited to phase Ia clinical trials).
- Patient has symptomatic brain metastases or meningeal metastases.
- The patient had symptomatic amyloidosis, active plasma cell leukemia, and active POEMS syndrome at the time of screening.
- There is evidence of cardiovascular risk, including any of the following: a. QTcF interval ≥ 470 ms (QT interval must be corrected by Fridericia formula [QTcF]). b. Evidence of currently clinically significant, untreated arrhythmias, including clinically significant electrocardiogram abnormalities such as degree 2 (Mobitz type II) or degree 3 atrioventricular conduction (AV) block. c. History of myocardial infarction, acute coronary syndrome (including unstable angina pectoris), coronary angioplasty, or stenting or bypass grafting within 6 months prior to screening. d. Grade III or IV heart failure(New York Heart Association Functional Grading System). e. Uncontrolled severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100 mmHg).
- The patient has difficulty breathing or currently requires continuous oxygen therapy, or currently has active pneumonia or interstitial lung disease (except for mild cases as determined by the investigator).
- The patient has a history of other primary malignancies, except the following: cured malignancies with a very low risk of recurrence within 5 years, such as skin basal cell carcinoma and skin squamous cell carcinoma, carcinoma in situ of the cervix or breast.
- Patients have severe unhealed wound ulcers or fractures, or have undergone major surgery within 28 days prior to dosing or are expected to undergo surgery during the clinical study.
- Previous history of allergy to any component or excipient of DXC006.
- Active hepatitis B (HBV-DNA greater than the central upper limit of normal or HBV-DNA testing greater than 1000 copies /mL); Hepatitis C infection (positive for hepatitis C antigen or positive for hepatitis C RNA PCR).
- Seropositive for human immunodeficiency virus (HIV); Active syphilis (patients with positive syphilis antibodies can be included); Possible active tuberculosis (chest imaging within 3 months prior to first dosing indicating active tuberculosis infection).
- Patients had active bleeding within 30 days prior to screening, or were at risk of massive gastrointestinal bleeding or hemoptysis as determined by researchers; Or have inherited bleeding tendencies or coagulation disorders, or bleeding symptoms that require other medical intervention.
- Severe arteriovenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism, occurred within 6 months before the first dose.
- Female patients with a positive serological pregnancy test or who are breastfeeding.
- Active infections requiring medical treatment (CTCAE≥2); Uncontrollable pleural fluid, ascites, pericardial effusion requiring repeated drainage;
- Received live attenuated vaccine within 28 days before the first dose.
- The patient has other conditions that the investigator or sponsor has determined may affect the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Dose Escalation DXC006, Cohort Expansion DXC006
|
Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort. Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants that experienced dose limiting toxicities(DLTs) at given dose level.
Time Frame: 28 days
|
Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated.
|
28 days
|
Number of participants with adverse events (AEs)
Time Frame: After first infusion of study drug, Through study completion an average of 1 year
|
The adverse events will be evaluated in accordance with CTCAE v5.0.
The investigator shall assess the relationship between the events and investigational product.
|
After first infusion of study drug, Through study completion an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR)
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
DOR is defined as the time from the date of the first documentation of response (confirmed CR or confirmed PR) to the date of the first documentation of PD or death due to any cause, whichever occurs first.
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
Overall Survival (OS)
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
OS is defined as the time from the date of randomization to the date of death due to any cause.
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
Maximum observed serum or plasma concentration (Cmax)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006investigator shall assess the relationship between the events and investigational product.
|
Through study completion an average of 1 year
|
Maximum serum drug time(Tmax)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Apparent volume of distribution(Vd)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Volume of distribution at steady state (Vss)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Terminal phase elimination half life (t½)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Area under the serum or plasma concentration time curve from 0 to the last measurable point (AUC0-t)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Area under the serum or plasma concentration time curve from 0 to infinity (AUC0-inf)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Clearance (CL)
Time Frame: Through study completion an average of 1 year
|
One of the pharmacokinetics parameters for DXC006.
|
Through study completion an average of 1 year
|
Anti-drug antibodies (ADA)
Time Frame: Through study completion an average of 1 year
|
The titer,neutralizing activity and positive rate of anti-drug antibody (ADA).
|
Through study completion an average of 1 year
|
Objective Response Rate (ORR)
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
As determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, which will be complete response (CR) + partial response (PR).
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
Progression Free Survival (PFS)
Time Frame: om date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
PFS is defined as the time from the date of randomization to the earlier of the dates of the first documentation of progressive disease or death due to any cause.
|
om date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prof. Zhang Li, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DXC006-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia